Abstract:OBJECTIVE Previous studies have demonstrated acetylcholine muscarinic 4（M4） receptor regulates DARPP-32 phosphorylation at Thr75 in isolated medium spiny neurons（MSNs）,indicating antagonistic mechanism with D1 dependent signal cascade,but the exact molecular mechanisms remain unclearly.In this study,we investigated the roles of M4 receptor in modulation D1 dependent signal to integrate striatal DA inputs in isolated MSNs.METHODS（1）Lentivirus technology was employed to genetically knock down the M4 receptor of MSNs;（2） Apomorphine（APO）,acts as a dopamine receptor agonist,while SCH23390,acts as a selective antagonist for D1,were used to study the pharmacologically profiles with D1 receptor stimulation or blockade,respectively.Then the no subtype-selective muscarinic agonist oxotremorine M（OX） were used to show that mAchRs activation,in order to dissect the particular function of M4,a selective M4 antagonist,MT3 was used;（3） Intracellular cAMP production of MSNs was measured by using time resolved fluorescence resonance energy transfer detection method;（4） Laser confocal was used to explore the expression of M4 and D1 in MSNs;（5） Immunofluorescence cytochemistry and Western blotting were used to confirm the alteration of signaling molecular including P-CREB,DARPP-32 P-Thr34,DARPP-32 P-Thr75,cyclin-dependent kinase 5（CDK5） as wel as p25/35,which are involved in DA-dependent signaling modulations.RESULTS Firstly,TR-FRET assay revealed APO(10-2 mol·L -1 )significantly increased the level of intracellular cAMP（vs control,n=3,P＜0.01）,also Western blotting results showed that APO(10-6 mol · L -1 )increased DARPP-32 Thr34 phosphorylation（vs control,n=3,P＜0.01）,and these effect were reversed by D1 receptor antagonist SCH23390（vs APO,n=3,P＜0.01）.Interestingly,we confirmed that OX(10-6 mol · L -1 ) down-regulated APO-induced DARPP-32 Thr34 phosphorylation（vs APO,n=3,P＜0.01）,due to its effects on DARPP-32 phosphorylation at Thr75.The results presented the antagonistic mechanism of mAchRs stimulation with D1 dependent signal cascade in MSNs.Meanwhile,OX(10-7,10-6 and10 -5 mol·L -1 ) stimulated DARPP-32 phosphorylation at Thr75,and simultaneously up regulated P25/35 and CDK5 activity（vs control,n=3,P＜0.01） by using Western blotting assay.Furthermore,roscovitine(10 -5 mol · L -1 ),acts as a CDK5 inhibitor,suppressed CDK5 activity（vs control,n=10,P＜0.01）,and fully inhibited OX-induced DARPP-32 Thr75 phosphorylation（vs OX,n=10,P＜0.01）.More important,pretreated with roscovitine(10 -5 mol·L -1 ),the effect of APO on DARPP-32 Thr34 phosphorylation was potentiated（vs APO,n=3,P＜0.05）.The result presented CDK5 is required in suppression of APO on DARPP-32 Thr34 phosphorylation mediated through mAchRs stimulation.In addition,laser confocal results showed that the CDK5 up-regulation was mostly confined to MSNs co-expressing M4,which means that M4 participated in CDK5-mediated phosphorylation of DARPP-32 at Thr75.Consistently,immunofluorescence and Western blotting results confirmed that both genetic knockdown and pharmacologic inhibition of M4 receptors with MT3(10-7 mol · L -1 ) down-regulated the OX-induced the expression of CDK5（vs OX,n=3,P＜0.01） and P25/35（vs OX,n=3,P＜0.01）in isolated MSNs.CONCLUSION M4 receptor may play an important role in antagonistic regulation D1 dependent signaling,in which CDK5 is required for suppressing D1-DARPP-32 Thr34 phosphorylation in isolated medium spiny neurons.

D(4) Dopamine Receptor Differentially Regulates Akt/nuclear Factor-Kappa B and Extracellular Signal-Regulated Kinase Pathways in D(4)MN9D Cells.

Dopamine D2 Receptor Modulates Wnt Expression and Control of Cell Proliferation

Regulation of D-1 Dopamine Receptors with Mutations of Protein Kinase Phosphorylation Sites: Attenuation of the Rate of Agonist-Induced Desensitization

ErbB4 Regulate Extracellular Dopamine Through the P38 MAPK Signaling Pathway.

7-OH-DPAT and PD 128907 Selectively Activate the D3 Dopamine Receptor in a Novel Environment

Cyclin-dependent kinase 5 is required for suppressing D1-dependent signaling mediated through muscarinic 4 in isolated medium spiny neurons

Cholera Toxin-Sensitive 3',5'-Cyclic Adenosine Monophosphate and Calcium Signals of the Human Dopamine-D1 Receptor: Selective Potentiation by Protein Kinase A

Activation of phosphatidylinositol-linked novel D1 dopamine receptors inhibits high-voltage-activated Ca2+ currents in primary cultured striatal neurons.

The Effects of D3R on TLR4 Signaling Involved in the Regulation of METH-mediated Mast Cells Activation.

Phosphorylation and Hetero‐oligomerization Regulate the Dopamine D3 Receptor/adenylyl Cyclase Type 5 Signaling Complex

Agonist-Induced Endocytosis and Receptor Phosphorylation Mediate Resensitization of Dopamine D2 Receptors

5-HT1A Receptor-Mediated Regulation of Mitogen-Activated Protein Kinase Phosphorylation in Rat Brain

Depletion of D3 Dopamine Receptor Affects Methamphetamine-Induced Expression Patterns of Pde4b and Atf3.

Activation of extracellular signal-regulated protein kinases is associated with a sensitized locomotor response to D(2) dopamine receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats.

Biased Signaling Agonists Promote Distinct Phosphorylation and Conformational States of the Dopamine D3 Receptor

Doparaine D-1 And D-3 Receptors Oppositely Regulate Nmda- And Cocaine-Induced Mapk Signaling Via Nmda Receptor Phosphorylation

Phosphorylation of the Δ-Opioid Receptor Regulates Its Β-Arrestins Selectivity and Subsequent Receptor Internalization and Adenylyl Cyclase Desensitization

Activation of Dopamine D1 Receptors Enhances the Temporal Summation and Excitability of Rat Retinal Ganglion Cells.

Heterologous Activation of Protein Kinase C Stimulates Phosphorylation of Δ-Opioid Receptor at Serine 344, Resulting in Β-Arrestin- and Clathrin-mediated Receptor Internalization

Protein kinase Cβ is a modulator of the dopamine D2 autoreceptor-activated trafficking of the dopamine transporter

Novel D3 Dopamine Receptor-Preferring Agonist D-264: Evidence of Neuroprotective Property in Parkinson'S Disease Animal Models Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Lactacystin